AbFero Pharmaceuticals Announces Funding From Cure Parkinson's For Lead Compound SP-420
AbFero Pharmaceuticals Announces Funding From Cure Parkinson's For Lead Compound SP-420 Second Parkinson's Grant to Clinical Stage Pharmaceutical Company Developing Iron Chelators HARWELL, England, Feb. 17, 2021 /PRNewswire/ -- AbFero Ltd., a subsidiary of AbFero Pharmaceuticals, Inc., a privately-held clinical stage pharmaceutical company dedicated to treating diseases of iron overload, today announced the award of a grant from Cure Parkinson's for the development of their lead, brain-penetrant iron chelating agent, SP-420, as a disease modifying therapy for Parkinson's disease (PD). The fu...
Source: finanznachrichten.de